Director Sean Whelan filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of Stock Appreciation Rights in Zomedica Corp. on November 16, 2026.

Key Highlights

  • Reporting Person: Sean Whelan, identified as a Director of Zomedica Corp.
  • Transaction Date: November 16, 2026, with the form filed November 17, 2026.
  • Derivative Security Acquired: 1,975,033 Stock Appreciation Rights, acquired with transaction code "A."
  • Exercise Price: $0.10 per Stock Appreciation Right, with a price of $0 reported for the acquisition.
  • Expiration Date: November 15, 2036, with the rights exercisable beginning November 15, 2027.
  • Underlying Security: 1,975,033 shares of Zomedica Corp. common stock.
  • Beneficial Ownership Following Transaction: 1,975,033 Stock Appreciation Rights held directly.

Whelan's Stock Appreciation Right Grant at Zomedica: Transaction Details

According to the filing, Sean Whelan, a Director of Zomedica Corp. (trading symbol ZOMDF), reported the acquisition of 1,975,033 Stock Appreciation Rights on November 16, 2026. The transaction was recorded under transaction code "A," indicating an acquisition. The filing lists a conversion or exercise price of $0.10 per right and a price of $0 for the derivative security at the time of acquisition.

The filing discloses that the Stock Appreciation Rights are exercisable beginning November 15, 2027, and expire on November 15, 2036. The underlying security associated with these rights is Zomedica Corp. common stock, with 1,975,033 shares underlying the grant. Following the reported transaction, Whelan's beneficial ownership in the derivative security stands at 1,975,033 Stock Appreciation Rights, held directly.

No non-derivative securities transactions were reported in Table I of the filing. The filing was submitted by one reporting person and was not indicated as an amendment to a prior filing. No Rule 10b5-1(c) plan designation was checked on the form.

What Was Disclosed

Sean Whelan, a Director of Zomedica Corp., disclosed the acquisition of 1,975,033 Stock Appreciation Rights on November 16, 2026, exercisable from November 15, 2027, through November 15, 2036, with an exercise price of $0.10, resulting in direct beneficial ownership of 1,975,033 rights.